Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Beam Therapeutics Inc. BEAM
$33.48
-$1.62 (-4.83%)
На 18:02, 12 мая 2023
+88.17%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
2562109371.00000000
-
week52high
73.27
-
week52low
27.77
-
Revenue
60920000
-
P/E TTM
-9
-
Beta
1.62891400
-
EPS
-4.06000000
-
Last Dividend
1.12500000
-
Next Earnings Date
08 мая 2023 г. в 10:30
Описание компании
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 10 авг 2022 г. |
| Barclays | Equal-Weight | Equal-Weight | 10 авг 2022 г. |
| BMO Capital | Market Perform | 17 июн 2022 г. | |
| SVB Leerink | Outperform | Outperform | 09 мая 2022 г. |
| Credit Suisse | Neutral | 28 апр 2022 г. | |
| Credit Suisse | Neutral | Neutral | 08 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 07 ноя 2022 г. |
| BMO Capital | Outperform | Market Perform | 20 дек 2022 г. |
| Citigroup | Buy | 13 дек 2022 г. | |
| Cantor Fitzgerald | Overweight | 01 февр 2023 г. | |
| SVB Leerink | Outperform | Outperform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Burrell Terry-Ann | D | 185565 | 36152 | 27 янв 2023 г. |
| Burrell Terry-Ann | D | 31277 | 36152 | 27 янв 2023 г. |
| Burrell Terry-Ann | A | 67429 | 36152 | 27 янв 2023 г. |
| Burrell Terry-Ann | D | 221717 | 1102 | 26 янв 2023 г. |
| Burrell Terry-Ann | D | 31277 | 1102 | 26 янв 2023 г. |
| Burrell Terry-Ann | A | 32379 | 1102 | 26 янв 2023 г. |
| Burrell Terry-Ann | D | 222819 | 14810 | 24 янв 2023 г. |
| Burrell Terry-Ann | D | 31277 | 14810 | 24 янв 2023 г. |
| Burrell Terry-Ann | A | 46087 | 14810 | 24 янв 2023 г. |
| Burrell Terry-Ann | D | 237629 | 5426 | 23 янв 2023 г. |
Новостная лента
7 CRISPR Stocks With the Best Long-Term Potential
InvestorPlace
30 янв 2023 г. в 19:10
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.
5 Top Stocks for February
The Motley Fool
29 янв 2023 г. в 05:45
These growth stocks have more room to run.
3 Great Growth Stocks Down 20% or More to Buy Now
The Motley Fool
27 янв 2023 г. в 09:37
These beaten-down stocks could be poised for major rebounds.
3 Stocks That Could Create Lasting Generational Wealth
The Motley Fool
15 янв 2023 г. в 05:50
Making money that spans generations requires thinking big.
10 Potential 10x Return Stocks For The Next 10 Years
Seeking Alpha
04 янв 2023 г. в 11:04
While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or industry specific.